Skip to main content

Detect Mgen with the FDA-cleared Aptima® Assay

Find the hidden STI that might be harming your patients.

Mycoplasma genitalium, or Mgen, is a bacterium that can cause cervicitis, pelvic inflammatory disease (PID), and male urethritis. It can coexist with other STIs and cause similar symptoms.
couple reviewing paperwork

Advanced testing amplifies awareness

*Study population included symptomatic and asymptomatic subjects for both sexes.

Mgen can be harmful if left untreated

Detected in up to 30% of women with clinical cervicitis2
  • Identified in up to 22% of PID cases2
  • Infected patients are 2 times more likely to acquire HIV3
Responsible for 30% of persistent or recurrent urethritis in men4

Additionally, Mgen coinfection is common in men

  • C trachomatis: 35%5
  • N gonorrhoeae: 14%5
  • C trachomatis and N gonorrheae: 19%5

With 1 test, diagnose the cause of your patient's symptoms and reduce risks of untreated infection.

  • Frequent urination
  • Abnormal vaginal or penile discharge
  • Vaginal irritation or itching
  • Pain during intercourse
  • Burning during urination
  • Abnormal vaginal bleeding between periods or after intercourse

  • Chlamydia
  • Gonorrhea
  • Trichomoniasis
  • Mgen

STI panels test for all 4 pathogens with 1 urogenital samplea

aSTI panels can be performed with any of the collection devices shown above.


Mgen can be highly resistant to first-line antibiotics; alternate treatment may be necessary to avoid serious complications.

Although STIs present with similar symptoms, each responds better to different medications. Mgen can be highly resistant to standard first-line antibiotics, in which case, other medications may be necessary to avoid serious complications.


Get the answers you and your patients need with 1 test from Quest

FDA-cleared Aptima Assay from Quest uses nucleic acid amplification testing (NAAT), the preferred method of detection per the CDC.6

All components of panels can be ordered separately: Chlamydia trachomatis RNA, TMA, Urogenital (test code 11361); Neisseria gonorrhoeae (test code 11362); Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital (test code 11363); SureSwab Trichomoniasis RNA, Qualitative, TMA (test code 19550); SureSwab Ureaplasma species Real-Time PCR (test code 91476); Trichomonas vaginalis RNA, Qualitative, TMA, Males (test code 90801); Mycoplasma genitalium, rRNA, TMA (test code 91475).

Test codes may vary by location. Please contact your local laboratory for more information.

 

​References:

  1. Gaydos CA, Manhart LE, Taylor SN, et al. Molecular testing for Mycoplasma Genitalium in the United States: Results from the Ames Prospective Multicenter Clinical Study. J Clin Microbial. 2019;57(11). doi:10.1128/jcm.01125-19
  2. CDC. Sexually Transmitted Infections Treatment Guidelines, 2021. Mycoplasma genitalium. Published July 22, 2021. Accessed September 13, 2021. https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm
  3. Napierala Mavedzenge S, Weiss HA. Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis. AIDS. 2009;23(5):611-620. doi:10.1097/QAD.0b013e328323da3e
  4. Ronda J, Gaydos CA, Perin J, et al Does the Sex Risk Quiz predict Mycoplasma genitalium infection in urban adolescents and young adult women? Sex Transm Dis. 2018;45(11):728-734.doi:10.1097/OLQ
  5. Mena, L., Wang, X., Mroczkowski, T. F., & Martin, D. H. (2002). Mycoplasma genitaliuminfections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis, 35(10), 1167–1173. https://doi.org/10.1086/343829
  6. Workowski KA. Bolan GA. CDC. Sexually transmitted diseases treatment guidelines. 2015. published correction appears in MMWR Recomm Rep. 2015;64(33):9241. MMWR Recomm Rep. 2015;64(RR-03):1-137

Universal screening with opt-out for CT/NG screening

The latest CDC Guidelines recommended considering universal screening with opt-out as part of routine care for all female patients ages 15 - 24.*
*Workowski KA, et al. MMWR. doi:10.15585/mmwr.rr7004a1

Click to learn more

Assessing high-risk patients

With rates of sexually transmitted infections (STIs) on the rise, assessing women who may be high-risk is more important than ever.

Click to learn more

STI webinar series

Listen to the experts as they discuss STI testing beyond Chlamydia trachomatis and Neisseria gonorrheae.

Click to learn more

Contact us

Contact us to receive additional information on our lab tests, services, and coverage

Contact us